Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of SRS Versus HA-WBRT for Brain Metastases From SCLC
NCT04804644Phase 3Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Jun 2021
- Primary completion
- Jun 2026
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) and brain metastases (2 arms), sponsored by NRG Oncology. Primary endpoint: Time to neurocognitive failure at 1 year. Started Jun 2021; status: active, not recruiting.
02
Conditions
small cell lung cancer (SCLC)brain metastases
Beyond the preview
Go deeper on NCT04804644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04804644.